Codelivery of Salinomycin and Chloroquine by Liposomes Enables Synergistic Antitumor Activity in Vitro

Fangyuan Xie,Siyue Zhang,Junjie Liu,Zhirong Gong,Kaixuan Yang,He Zhang,Ying Lu,Hao Zou,Yuan Yu,Yan Chen,Zhiguo Sun,Xinxia Wang,Hai Zhang,Guoqing Zhang,Wei Li,Bohua Li,Jie Gao,Yanqiang Zhong
DOI: https://doi.org/10.2217/nnm-2016-0125
2016-01-01
Nanomedicine
Abstract:Aim: To improve the suboptimal therapeutic efficacy of salinomycin (SAL) toward liver cancer cells using chloroquine (CQ) combination by the liposomes co-delivering SAL and CQ (SCNL). Materials & methods: The synergy of these two drugs was evaluated in liver cancer cells (HepG2) and liver cancer stem cells (LCSCs) by median-effect analysis. SCNL with optimized ratio were developed. The cytotoxic effect and basal autophagy flux (measure of autophagic degradation activity) of various formulations were evaluated. Results & conclusion: CQ could significantly increase the cytotoxic effect of SAL in HepG2 cells, but not in HepG2-LCSCs, due to the greater basal autophagy flux in HepG2 cells. This combination therapy is promising for liver cancer treatment by eradicating liver cancer cells and LCSCs.
What problem does this paper attempt to address?